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EgyptiansAbstract Background: Cathepsin C gene (CTSC) (MIM#602365) is a lysosomal cysteine pro-
teinase coding gene which encodes for CTSC protein that plays a major role in the activation of
granule serine proteases, particularly leukocyte elastase and granzymes A and B. This activity
was proposed to play a role in epithelial differentiation and desquamation. Mutations that cause
Disruption in the CTSC expression or function will result in loss of immunological response such
as defects of phagocytic function and deregulation of localized polymorphonuclears response with
subsequent clinical manifestation.
Aim: The aim of this study is to detect the mutation in CTSC gene expected to be the cause of
Papillon Lefe`vre syndrome (PLS) in an Egyptian patient clinically diagnosed as PLS and to
characterize the clinical features.
Patient and methods: A 5 year and 3 month old girl from the outpatient’s Oro-Dental Genetics
clinic – National Research Center presented with the typical clinical ﬁndings of Papillon Lefevre
syndrome. Genomic DNA was extracted from peripheral blood samples of the patient, her parents
and 20 healthy Egyptian controls using standard procedures. All exons of the CTSC gene were
ampliﬁed by PCR. Sequence analysis of the patient, her parents and controls was performed for
mutation detection.
Results: Mutation analysis of the CTSC gene in our patient revealed a novel homozygous non-
sense mutation in exon 5 (W237X). Her parents revealed the presence of the same mutation in a
heterozygous state. The 20 controls showed only the wild type sequence of all exons (no mutation).
Conclusion: This study reported a novel nonsense mutation in the CTSC gene in an Egyptian
patient. This novel nonsense mutation is predicted to produce truncated dipeptidyl-peptidase1 caus-
ing PLS phenotype in this patient.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Papillon Lefe`vre syndrome (PLS) is an autosomal recessive
disorder characterized by aggressive periodontitis and
palmoplantar hyperkeratosis [1]. It has a world-wide preva-
lence of 1–4 cases per million in the general population and
is often related with consanguinity [2]. Dermatological disor-
ders initiate with erythema and after about 6 months, they pro-
gress to hyperkeratosis of soles, palms, knees, and elbows. The
major feature of Papillon Lefevre syndrome is severe periodon-
titis. Patients typically report two episodes of aggressive
periodontitis: the ﬁrst one around three years of age, leading
to the loss of primary teeth [3], the second around ﬁfteen years
of age, resulting in the loss of permanent teeth [4].
The development and eruption of the deciduous teeth
proceed normally, at expected ages and with normal sequence,
with the teeth being of normal form and structure, but their
eruption is associated with gingival inﬂammation and subse-
quent rapid destruction of the periodontium. The resulting
periodontitis is usually unresponsive to traditional periodontal
treatment modalities and the primary dentition is usually
exfoliated prematurely by the age of 4 years. After exfoliation,
the inﬂammation subsides and the gingiva appears healthy.
However, with the eruption of the permanent dentition, the
process of gingivitis and periodontitis is usually repeated and
there is subsequent premature exfoliation of the permanent
teeth, although the third molars are sometimes spared, where
most of the permanent teeth are lost by the age of 15 and
17 years, often leaving the jaws atrophied. The tooth loss pat-
tern often mimics the eruption pattern [5]. Severe resorption of
the alveolar bone gives the teeth the ‘‘ﬂoating in air" appear-
ance on radiographs. However, others have found variable
penetrance and less severe periodontal disease [4,6–10].
In addition to these symptoms, recurrent skin infections,
liver abscesses, mild mental retardation, intracranial calciﬁca-
tions, and hyperhidrosis have been reported [11].
The Cathepsin C gene (CTSC) is expressed in epithelial
regions commonly affected by PLS such as palms, soles, knees
and gingiva [12]. The loss of CTSC function and subsequent
inactivity of neutrophil serine proteinases [13,14] as well as
reduced neutrophil response to staphylococcus spp. and
Actinobacillus actinomycetemcomitans lead to the severe
periodontal tissue destruction [15].
The CTSC gene maps to chromosome 11q14.2, spans
4.7 kb and has seven exons and six introns [16–18].
Mutations in both alleles of CTSC gene have been reported
as responsible for Papillion Lefevre Syndrome (PLS; OMIM
245000) [19,20] as well as similar conditions such as Haim–
Munk Syndrome (HMS, OMIM 245010), and juvenile period-
ontitis (AP1, OMIM 170650).
In 1999, the ﬁrst eight mutations of the CTSC gene were
identiﬁed in 8 cases from consanguineous PLS parents [20].
Since 1999, several reports have described mutations in the
CTSC gene in different PLS cases from around the world
[21]. CTSC mutations have also been reported in patients with
Haim–Munk syndrome (HMS, OMIM 245010) and in aggres-
sive periodontitis (AP1, OMIM 170650), [22–24]. To date, a
total of 75 mutations have been reported for the CTSC gene.
The majority of the mutations (97%) were reported in PLS
cases, while only a few mutations (3%) were reported in
HMS or AP1 cases. Most mutations are missense (53%),nonsense (23%), or frameshift (17%); however, in-frame dele-
tions, one splicing variant, and one 50 untranslated region
(UTR) mutation have also been reported. The majority of
the mutations are located in exons 5–7, which encodes the
heavy chain of the cathepsin C protein, suggesting that
tetramerization is important for cathepsin C enzymatic activity
[21]. Note that some mutations were detected in two different
disease entities: c.1040A>G p.Tyr347Cys was reported for
AP1 and also for classic PLS families [20,22–24], c.145C>T
p.Gln49X and c.857A>G p.Gln286Arg mutations were
reported for HMS and PLS pedigrees [25,26]. Therefore,
PLS, HMS, and AP1 are not different entities; they represent
the phenotypic spectrum of a single disease [27].2. Patient and methods
2.1. Patient’s clinical data
A 5 year and 3 month old girl came to the outpatient’s
Oro-Dental Genetics clinic – National Research Center and
presented with the typical clinical ﬁndings of Papillon Lefevre
syndrome as described by Papillon & Lefevre in 1924 [1]. Her
chief complaint was early loss of her anterior teeth by the age
of 3 yrs. The girl was born out of a consanguineous marriage,
with two unaffected siblings. Intraoral examination revealed
generalized aggressive periodontitis with premature loss of
the four primary central incisors. Dermatological examination
revealed mild localized keratotic plaques on both the palms and
soles which according to her mother, responded very well to the
retinoids therapy, which started seven months ago
(Fig. 1a and b). The gingiva was edematous with loss of stip-
pling. Grade III mobility was noticed in the upper canines
which explains the discomfort described by the patient while
eating. Pocket probing depths of the remaining teeth were on
average of 4–6 mm (Fig. 1c and d).
2.2. Molecular studies
Our study has been carried out in accordance with The Code
of Ethics of the World Medical Association for experiments
involving humans. Written informed consent was obtained
from the patient’s parents and 20 healthy Egyptian controls,
according to Medical Ethics Committee of the National
Research Center.
Genomic DNA was extracted from peripheral blood sam-
ples using standard procedures. All exons of the CTSC gene
were ampliﬁed by PCR using intron-speciﬁc primers [20],
except for the developed primer pairs for exons 1 and the 50
half of exon 7 (Table 1)]. PCR was performed in a ﬁnal volume
of 25 ll containing 100 ng genomic DNA, MgCl 2
(1.5 m M), dNTP mixture (0.2 m M), Taq DNA polymerase
(2 U/ll), and 10 lM of each primer (MWG-BIOtech,
Ebersberg, Germany).
Conditions of PCR comprised 1 cycle of denaturation at
95 C for 2 min followed by 35 cycles of 30 s at 94 C, 30 s
at annealing temperature (Tm primer), and 1 min extension
at 72 C followed by a ﬁnal extension at 72 C for 7 min in a
thermal cycler (Agilent Technologies Sure Cycler 8800). 5 ll
aliquots of the PCR products were analyzed by 2% agarose
gel electrophoresis.
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Puriﬁcation kit (Qiagene) followed by bidirectional sequencing
using the ABI Prism Big Dye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems) and the sequencing reac-
tion products were separated on an ABI Prism 310 Genetic
Analyzer (Applied Biosystems). Alignment of sequenced
results used NCBI genomic sequence NG_008365.1 and refer-
ence cDNA sequence NM_000348.3 for result interpretation.
3. Results
Mutation analysis of the CTSC gene in our patient revealed a
homozygous nonsense mutation in exon 5 at the nucleotide
position c.711 (TGG was replaced by TAG, c.711G>A) result-
ing in a premature stop codon instead of tryptophan at codon
237 (p.W237X) (Fig. 2A). Sequence analysis of CTSC gene forFigure 1 (a and b) showing palmoplantar hyperkeratosis, (c and d) s
edematous with loss of stippling.
Table 1 Sequence of forward and reverse primers of exons1–7 of C








7b 50-CAATGAAGCCCTGATCAAGC-30her parents revealed the presence of the same mutation
(W237X) in a heterozygous state (Fig. 2B). Her mother carries
the heterozygous form of the T153I variant (resulting in the
substitution of Isoleucine (ATA) by Threonine (ACA) at codon
153) and her father carries the wild type form. On the other
hand, the 20 control individuals showed only the wild type
sequence of exon 5 (no mutation) (Fig. 2C). With respect to
T153I variant in the control group 2 carried the homozygous
form, 2 were heterozygous and the rest were wild type. The
patient also disclosed the wild type variant T15 I in exon 3.
4. Discussion
CTSC gene (MIM#602365) also named dipeptidyl-peptidase I
(DPPI) is a lysosomal cysteine proteinase, which plays an
important role in intracellular degradation of proteins and alsohowing severe periodontitis related to primary teeth, the gingiva is
TSC gene.









Figure 2 Sequence chromatogram of the detected mutation: (A) sequence of exon 5 of CTSC gene at codon 237 showing W237X
homozygous mutation (patient), (B) codon 237 showing W237X heterozygous mutation (parents), (C) the wild type of codon
237(controls).
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ﬂammatory cells [28]. The CTSC gene locus has been mapped
to a 2.8 cm interval on chromosome 11q14, ﬂanked by
D11S4197 and D11S931 [19,29,30].
Up till now, approximately 75 different mutations have
been reported worldwide on the CTSC gene [21]. Of these
mutations, 85% were present only in homozygous form in
PLS patients, while 15% were detected in a compound
heterozygous state. Among the homozygous mutations, 50%
were missense, 25% nonsense, 23% frameshift mutations,
and 2% were other types of mutations [21].
All CTSC mutations have either a dramatic impact on the
coding region (nonsense, frameshift, or splicing mutations) or
have altered evolutionarily conserved amino acids (missense)
[8–10,31].
Nonsense mutations occur in all coding regions of the gene;
however, the majority is located in exons 5–7, encoding the
heavy-chain region of the cathepsin C protein which is thought
to be important for enzyme activity [32].
Genetic testing of the current case revealed the presence of
a novel homozygous nonsense mutation in exon 5
(c.711G>A), leading to the substitution of Tryptophan amino
acid to a stop codon at codon 237 (p.W237X) resulting in the
truncation of the CTSC encoded enzyme dipeptidyl-peptidase
1 with the introduction of premature stop codon.
The nucleotide change reported here (W237X) fulﬁlled the
criteria of a mutation [33] as it was not present in the 20 con-
trols and results in the truncation of the CTSC encoded enzyme
dipeptidyl-peptidase1 with the introduction of premature stop
codon.Table 2 Summary of studies reporting mutations in CTSC gene in
Site Mutation Amino acid Type of mutation
Intron 3 c.485-1G>A c.IVS3-1G>A Splice site
Exon 4 c.628C>T R210X Nonsense
Exon 5 c.711 G>A W237X* Nonsense
c.755 A>T Q252L Missense
Exon 7 c.1015 C>T R339C Missense
* Novel mutation.In addition to mutations of the CTSC gene, it is impor-
tant to note that the c.458C>T p.Thr153Ile missense variant
is a common polymorphisms for this gene and corresponds to
variant rs217086, occurs at a residue that is conserved in
mammals and is located in the portion of the propeptide that
is cleaved upon activation [34]. The Thr153Ile polymorphism
has been indentiﬁed in several PLS families, but does not
have a causative role in the development of PLS
[13,27,35,36].
Thr153Ile polymorphism occurs at a residue conserved
between humans and dogs and is in the portion of the pro-
region that is normally cleaved out upon activation. Given that
the T153I polymorphism occurs within 10 amino acids of the
N-terminal cleavage site, it is attractive to hypothesize that
the mutation interferes with or prevents this normal
processing.
Comparison of clinical features in affected families with the
same mutation strongly conﬁrms that identical mutations of
the CTSC gene can give rise to multiple different phenotypes,
making genotype–phenotype correlations difﬁcult [37].
Four mutations were previously described in Egyptian
patients with PLS (Table 2). These mutations are c.IVS3-
1G>A, R210X, Q252L and R339C (20, 22, 38, 39 and unpub-
lished data). With respect to the ethnicity of these mutations
and the fact of high consanguineous marriage rate among
Egyptian population which represent more than 30% [40]
these mutations are mostly attributed to a founder gene effect
due to the neighborhood of the Arab countries, the British
occupation to Martinique and Egypt and the Turkish occupa-
tion to Egypt.Egyptian patients and their repetition in other populations.
Ethnicity Ref.
Egyptian, Jordanian [20,38] and unpublished data
Egyptian, Lebanese, Algeria [20,39] and unpublished data
Egyptian The present study
Egyptian [20]
Egyptian, Martinique, Turkish [20,22,39] and unpublished data
Nonsense mutation in cathepsin C gene in a patient with Papillon–Lefe`vre syndrome 391In conclusion, we have detected a novel nonsense homozy-
gous mutation in the CTSC gene, extending the spectrum of
mutations in the CTSC gene.Conﬂict of interest
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